Foghorn Therapeutics (FHTX) EBITDA (2019 - 2026)

Foghorn Therapeutics' EBITDA history runs 8 years deep, the most recent figure standing at -$20.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 5.68% year-over-year to -$20.0 million; the TTM figure through Mar 2026 stood at -$75.5 million (up 5.58% YoY), while the FY2025 annual figure was -$74.4 million, up 13.15% from the prior year.
• EBITDA was -$20.0 million for Q1 2026 at Foghorn Therapeutics, up from -$21.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$13.5 million in Q3 2023 to a low of -$29.4 million in Q1 2023.
• Historically, EBITDA has averaged -$22.8 million across 5 years, with a median of -$22.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: EBITDA surged 50.74% in 2023, then plunged 36.28% in 2024.
• A 5-year view of EBITDA shows it stood at -$28.0 million in 2022, then grew by 17.74% to -$23.0 million in 2023, then rose by 14.37% to -$19.7 million in 2024, then declined by 9.81% to -$21.7 million in 2025, then grew by 7.53% to -$20.0 million in 2026.
• The last three EBITDA figures came in at -$20.0 million (Q1 2026), -$21.7 million (Q4 2025), and -$15.8 million (Q3 2025), per Business Quant data.